04/15/2014 - 11:45am

The Food and Drug Administration on Tuesday announced that it approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.

04/09/2014 - 10:47am

Omnis Health on Tuesday announced the launch of EmbracePro, a blood-glucose meter for medical professionals.

04/03/2014 - 8:55am

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

03/28/2014 - 11:20am

Novo Nordisk on Friday launched "Cities Changing Diabetes," a new partnership program to fight the urban diabetes challenge.

03/26/2014 - 9:44am

In a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease, adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study in the March 26 issue of JAMA.

03/17/2014 - 9:48am

Abbott voluntarily recalled the FreeStyle Blood Glucose Meter and the FreeStyle Flash Blood Glucose Meter, neither of which have been in production since 2010.

03/06/2014 - 2:20pm

Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.

03/03/2014 - 2:48pm

An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday.

03/03/2014 - 12:26pm

AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.